DORIBAX POWDER FOR SOLUTION

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

DORIPENEM (DORIPENEM MONOHYDRATE)

זמין מ:

JANSSEN INC

קוד ATC:

J01DH04

INN (שם בינלאומי):

DORIPENEM

כמות:

500MG

טופס פרצבטיות:

POWDER FOR SOLUTION

הרכב:

DORIPENEM (DORIPENEM MONOHYDRATE) 500MG

מסלול נתינה (של תרופות):

INTRAVENOUS

יחידות באריזה:

500ML

סוג מרשם:

Prescription

איזור תרפויטי:

CARBAPENEMS

leaflet_short:

Active ingredient group (AIG) number: 0152649001; AHFS:

מצב אישור:

CANCELLED POST MARKET

תאריך אישור:

2013-07-03

מאפייני מוצר

_DORIBAX 163140 APM.doc _
_ _
_Page 1 of 47 _
PRODUCT MONOGRAPH
PR
DORIBAX
®
Doripenem for Injection
500 mg/vial doripenem (as doripenem monohydrate)
Antibacterial Agent
ATC code: J01DH04
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen.ca
Date of Revision:
June 14, 2013
Submission Control No: 163140
All trademarks used under license.
© 2013 Janssen Inc.
_DORIBAX 163140 APM.doc _
_ _
_Page 2 of 47 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..................................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................................
8
DRUG INTERACTIONS
............................................................................................................................................
12
DOSAGE AND ADMINISTRATION
........................................................................................................................
13
OVERDOSAGE
..........................................................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................................
17
STORAGE AND STABILITY
.........................................................................................